AstraZeneca: Vaccine Is 79% Effective In U.S. Trials

AstraZeneca's US trial shows its COVID-19 vaccine is 79% effective in preventing symptomatic disease. The vaccine is already approved in many countries outside the US, and the company plans to seek emergency authorization in the US soon. Despite some European countries pausing its use due to blood clot concerns, health officials found no link between the vaccine and these incidents, declaring it safe. However, a poll indicates that public perception in Europe has been negatively affected, with many viewing the vaccine as unsafe.

What was the effectiveness of AstraZeneca's COVID vaccine in the US trial?

• 85%

• 90%

• 79%

• 95%

How many participants were involved in AstraZeneca's US trial?

• Over 50,000

• Over 10,000

• Over 20,000

• Over 32,000

Why did some European countries temporarily stop using the AstraZeneca vaccine?

• Due to reports of blood clots

• Due to storage issues

• Due to low effectiveness

• Due to high cost

What did European health officials conclude about the AstraZeneca vaccine and blood clots?

• There is no link

• There is a strong link

• The vaccine is ineffective

• The link is unclear

According to a poll, what percentage of French adults view the AstraZeneca vaccine as unsafe?

• 61%

• 50%

• 70%

• 43%